Cancer cell-derived small extracellular vesicles bind to therapeutic nanoparticles leading them from tumours to the liver for degradation. This mechanism is another barrier for the development of efficient nanoparticle-based cancer therapies.
- Ningqiang Gong
- Wenqun Zhong
- Michael J. Mitchell
